These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 151900)

  • 21. Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.
    Falkson G; MacIntyre JM; Schutt AJ; Coetzer B; Johnson LA; Simson IW; Douglass HO
    J Clin Oncol; 1984 Jun; 2(6):581-4. PubMed ID: 6327926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in antitumor antibiotics.
    Umezawa H
    Antibiot Chemother (1971); 1978; 23():76-87. PubMed ID: 77145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic effects of perioperatively administered neocarzinostatin in renal cell carcinoma.
    Satake I; Tari K; Ohwada F; Saitoh T; Negishi T
    Nihon Gan Chiryo Gakkai Shi; 1989 Apr; 24(4):809-16. PubMed ID: 2528598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neocarzinostatin: a phase I clinical trial with five-day intermittent and continuous infusions.
    McKelvey EM; Burgess MA; McCredie KB; Murphy WK; Bodey GP
    Cancer; 1979 Oct; 44(4):1182-8. PubMed ID: 159119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neocarzinostatin: report of a phase II clinical trial.
    McKelvey EM; Murphy W; Zander A; Bodey GP
    Cancer Treat Rep; 1981; 65(7-8):699-701. PubMed ID: 6454486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zinostatin-related pulmonary toxicity.
    Calvo DB; Legha SS; McKelvey EM; Bodey GP; Dail DH
    Cancer Treat Rep; 1981; 65(1-2):165-7. PubMed ID: 6452946
    [No Abstract]   [Full Text] [Related]  

  • 27. Antimetastatic and antitumor activity of a derivative of neocarzinostatin: an organic solvent- and water-soluble polymer-conjugated protein.
    Maeda H; Takeshita J; Kanamaru R; Sato H; Khatoh J; Sato H
    Gan; 1979 Oct; 70(5):601-6. PubMed ID: 160353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Reductive effect on ascites, of neocarzinostatin in patients with ovarian cancer].
    Takahashi K; Watanabe M; Kikuchi J; Kishi H; Saito K; Mouri H; Ikeno N; Endo H; Shima I; Morizuka T
    Gan To Kagaku Ryoho; 1988 May; 15(5):1777-81. PubMed ID: 2967052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacology of the anticancer polypeptide neocarzinostatin.
    Hall SW; Knight J; Broughton A; Benjamin RS; McKelvey E
    Cancer Chemother Pharmacol; 1983; 10(3):200-4. PubMed ID: 6222845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary reaction associated with neocarzinostatin therapy.
    Seltzer SE; Griffin T; D'Orsi C; Tryka F; Herman PJ
    Cancer Treat Rep; 1978 Aug; 62(8):1271-2. PubMed ID: 150944
    [No Abstract]   [Full Text] [Related]  

  • 31. Phase II trial of zinostatin in children with late-stage acute lymphocytic leukemia: a Pediatric Oncology Group Study.
    Sexauer C; Kim T; Nix W; Berry DH; Morgan S
    Cancer Treat Rep; 1981; 65(1-2):173-4. PubMed ID: 6452947
    [No Abstract]   [Full Text] [Related]  

  • 32. Chromosome aberrations induced by neocarzinostatin in cultured human lymphocytes.
    Tsuda S
    Nihon Ketsueki Gakkai Zasshi; 1987 Feb; 50(1):65-78. PubMed ID: 2954359
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibitors of proteolytic enzymes prevent the inactivation by blood of the protein antibiotic neocarzinostatin and its succinyl derivative.
    Maeda H; Takeshita J
    J Antibiot (Tokyo); 1976 Jan; 29(1):111-2. PubMed ID: 132416
    [No Abstract]   [Full Text] [Related]  

  • 34. Pre-neocarzinostatin, a specific antagonist of neocarzinostatin.
    Kikuchi M; Shoji M; Ishida N
    J Antibiot (Tokyo); 1974 Oct; 27(10):766-74. PubMed ID: 4281770
    [No Abstract]   [Full Text] [Related]  

  • 35. [Neocarzinostatin therapy of advanced renal cell carcinoma].
    Tari K; Satake I; Kojima S; Tsujii T; Yonese J
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2719-23. PubMed ID: 2970825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of meningeal carcinomatosis--neocarzinostatin perfusion therapy in the CSF pathway].
    Uemura S; Matsukado Y; Fujioka S; Kuratsu J; Sonoda H; Yano T; Ohtsuka T; Yoshioka S
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1794-800. PubMed ID: 2931051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of PALA, amsacrine, teniposide, and zinostatin in small cell lung carcinoma (EST 2579).
    Creech RH; Tritchler D; Ettinger DS; Ferraro JA; Ruckdeschel JC; Vogl SE; Woll J
    Cancer Treat Rep; 1984 Sep; 68(9):1183-4. PubMed ID: 6090017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluorophotometric enzyme immunoassay of neocarzinostatin using peroxidase as a label.
    Matsuoka K; Maeda M; Tsuji A
    Chem Pharm Bull (Tokyo); 1980 Jun; 28(6):1864-8. PubMed ID: 6447549
    [No Abstract]   [Full Text] [Related]  

  • 39. [Principle and therapeutic effect of lipophilic anticancer agent [SMANCS/lipiodol]: selective targeting with oily contrast medium].
    Maeda H
    Gan To Kagaku Ryoho; 1989 Oct; 16(10):3323-31. PubMed ID: 2552930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Studies on the stability of antitumor protein, neocarzinostatin. II. Stability of injection of neocarzinostatin (author's transl)].
    Kono M; Ishii F; Haneda I; Koyama Y; Kikuchi M
    Jpn J Antibiot; 1974 Dec; 27(6):715-24. PubMed ID: 4282495
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.